LILRB4 Inhibitor
-
Rolistobart
0 ImagesCat. No.: HY-P990092CAS No.: 2723442-10-0Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic.
-
IO-202
0 ImagesCat. No.: HY-P992389IO-202 is a high-affinity LILRB4/ILT3 binder and myeloid checkpoint inhibitor. IO-202 blocks APOE binding and LILRB4 activation to reverse T-cell suppression and enhance T-cell cytotoxicity, while eliminating LILRB4-high-expressing leukemic blasts via ADCC and ADCP mechanisms. IO-202 promotes dendritic cell maturation and antigen presentation, reshapes the phenotype of tumor-associated macrophages, and reduces myeloid-derived suppressor cells. IO-202 is widely applicable to research on relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors.
-
TRX385
0 ImagesCat. No.: HY-P991308TRX385 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. TRX385 can be used in anticancer and antiviral research.
-
BND-35
0 ImagesCat. No.: HY-P991307BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model.
